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Clusterin protects against oxidative stress in vitro through aggregative
and nonaggregative properties. Perturbations of cell interactions, an early
event in acute renal injury, have important pathophysiologic conse-
quences. We hypothesized that promotion of cell interactions protects
cells from injury. To test this hypothesis, a single cell suspension of
LLC-PK1 cells (porcine proximal tubular cell line) treated with albumin
(control) was compared to cells aggregated with fibrinogen or purified
human clusterin (aggregation graded 0 to 4). Following aggregation, the
cells were injured with 1.5 mM hydrogen peroxide (H2O2) for three hours.
Cell aggregation induced by clusterin but not fibrinogen protected against
oxidant injury by H2O2. Complete abrogation of cytotoxicity occurred at a
clusterin concentration of 2.5 mg/ml, which resulted in an aggregation
score of 1. In the absence of aggregation, clusterin at concentrations of 20
and 50 mg/ml, but not lower doses, partially protected against injury
induced by H2O2. Cell aggregation induced by both clusterin and fibrin-
ogen partially protected against endogenously generated oxidant stress
induced by incubating LLC-PK1 cells with aminotriazole and 1-chloro-2,4-
dinitrobenzene (CDNB). In conclusion, clusterin protects against models
of oxidant stress in vitro, whether generated by exogenously administered
hydrogen peroxide, or from endogenously produced peroxide, and such
protective effects can accrue from aggregative and nonaggregative prop-
erties of clusterin.
Clusterin, a heterodimeric glycoprotein, is widely and promi-
nently induced in injured tissue, particularly when such injury
involves the kidney and the brain [1]. While the function of
clusterin in such states of injury remain uncertain, a number of
studies point to cytoprotective actions of clusterin induced in such
settings [2–6].
Clusterin induces aggregation of some but not all cells in vitro
and also is a potent cell adhesion molecule [7–9]. Prolonged
incubation of cells with clusterin results in the formation of
junctional contacts between cells and expression of cell adhesion
molecules [8, 9]. Clusterin may also be involved in more complex
cell interactions. For example, when vascular smooth muscle cells
are grown in culture they generate morphologically differentiated
nodules. Clusterin is differentially expressed in these nodules with
a time course, suggesting a role in nodule formation [10, 11].
Addition of anti-clusterin antibodies but not control antibodies
inhibits nodule formation [11]. Furthermore, clusterin is ex-
pressed during ontogeny at sites where critical cell interactions are
taking place, such as the branching bronchial tree and in the
ureteric bud prior to mesenchymal condensation [12, 13].
Abnormalities in cell interactions occur following renal injury
leading to cell rounding, retraction and detachment; decreased
binding of cells to matrix components is also recognized as well as
aberrant cell-cell attachments [14–20]. Loss of intercellular con-
tact may also induce apoptosis [21]. The loss of cell-cell and
cell-substratum interactions incurs detachment of tubular epithe-
lial cells and in turn, denudation of the epithelium and tubular
back leak of filtrate. Thus, even mild injury can lead to profound
nephron dysfunction mediated in part through alterations in cell
attachment. Loss of normal cell interactions from their usual
cellular contacts and substratum lead to variable effects on
cellular viability. On the one hand, cells so removed may be
otherwise intact, as evidenced by the presence of viable tubular
epithelial cells recoverable from the urine in patients with acute
renal failure [22]. On the other hand, the loss of these contacts
may lead to cell death; for example, MDCK cells undergo
apoptosis if they are prevented from attaching to culture plates
[23]. The term “anoikis” has been used to describe this phenom-
enon. Similarly, human endothelial cells undergo apoptosis when
cell-matrix interactions are inhibited [24]. In the setting of renal
injury, promoting cell-cell contacts may enhance cell survival by
allowing the exchange of critical nutrients or other factors be-
tween cells, or by providing the correct intracellular signals to
prevent apoptosis. Promoting cell-substratum contacts would pre-
vent sloughing of cells. In addition, maintenance of cell proximity
would allow the normal junctional contacts to become re-estab-
lished once the phase of injury subsides and the processes of
repair and regeneration are initiated.
The prominent induction of clusterin in tubules following injury
coupled with the capacity of this protein to promote cell interac-
tions led us to hypothesize that the induction of clusterin in states
of injury provides an adaptive response that attenuates injury that
otherwise occurs. We thus tested whether clusterin could protect
renal tubular epithelial cells from injury induced by a recognized
pathway of renal injury, namely, oxidative stress. We studied two
forms of oxidative stress: one was induced by the extracellular
application of reagent hydrogen peroxide. The other was induced
by a combined chemical manipulation that impaired intracellular
scavenging mechanisms for hydrogen peroxide, a model based on
the application of aminotriazole, an inhibitor of catalase, and
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1-chloro-2,4-dinitrobenzene (CDNB), a consumer of cellular glu-
tathione [25].
METHODS
Experimental protocols
Cell culture. Porcine renal epithelial (LLC-PK1) cells were
obtained from the American Type Culture Collection (Rockville,
MD, USA) at passage number 196. All experiments were per-
formed between passage numbers 196 and 206. Cells were grown
at 37°C in 95% air and 5% carbon dioxide in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma Chemical Co., St. Louis, MO,
USA) with 10% fetal bovine serum (Gibco BRL), L-glutamine
(330 mg/ml), Hepes (5.96 mg/ml), sodium bicarbonate (3.7 mg/
ml), penicillin (100 U/ml), and streptomycin (100 mg/ml).
Clusterin purification. Clusterin was purified from fresh human
serum by immunoaffinity chromatography as described previously
[9]. The column contained the mouse anti-human clusterin mono-
clonal antibody G7 (gift of Brendan Murphy, Melbourne, Austra-
lia). After the sample was applied to the column, the column was
sequentially washed with: 20 ml of 10 mM phosphate, 500 mM
sodium chloride, 10 mM EDTA, pH 7.4; 20 ml phosphate buffered
saline (PBS; Sigma) containing 0.5% Triton X-100 (Research
Organics, Cleveland, OH, USA); and finally 30 ml PBS. Clusterin
was eluted with a 0.2 M glycine-hydrochloride, 0.5 M NaCl solution
(pH 2.8) and neutralized with 1 ml of 2 mM Tris-HCl buffer (pH
7.0). The clusterin sample was further purified in a protein A
column to remove any immunoglobulin. Purity was documented
by SDS-PAGE and concentration determined by the Coomassie
blue dye method of Bradford. using BSA (fraction V powder;
Sigma) as a standard [26].
Hydrogen peroxide injury after aggregation. The following were
added to different wells of a 96 U-shaped well polyprostyrene
microtiter plate (Costar Corp., Cambridge, MA, USA): clusterin
(various concentrations), bovine serum albumin (50 mg/ml BSA;
Sigma) as a negative control, and fibrinogen (50 mg/ml; Sigma) as
a positive control. A single cell suspension was made from
LLC-PK1 cells that were grown to near confluence in a 75 cm
2
flask. Cells were detached using 0.25% trypsin in HBSS with 0.2
g/l EDTA (Hyclone Laboratories, Logan, UT, USA), resus-
pended in full media and then washed twice with PBS. The cell
suspension was added to each well to a final concentration of 4 3
105 cells/ml in a volume of 100 ml. Six wells were used for each
experimental group. The plate was mounted at a 45° angle and
rotated at 2 rpm in an incubator at 37°C in 95% air and 5% carbon
dioxide in the incubator. After 60 to 90 minutes of rotation, the
degree of aggregation was quantitated on a scale of 0 to 4 using
the method of Fritz and Burdzy [7, 27]. No aggregation was scored
as 0 and a tightly packed aggregate of cells was scored as 4. The
continuum between these values was denoted 1, 2, or 3 (Fig. 1).
To induce injury, hydrogen peroxide (1.5 mM) was added and the
cytotoxicity was quantitated three hours later using percent spe-
cific 51Cr or LDH release.
Hydrogen peroxide injury without aggregation. LLC-PK1 cells
were injured using the above protocol except the cell suspension
was added to 96 well flat-bottom plates (Costar Corp., Cambridge,
MA, USA), which for unclear reasons is associated with no cell
aggregation. Injury was measured as percent specific 51Cr release.
Aminotriazole/CDNB injury after aggregation. This is a model of
intracellularly generated oxidant stress via inhibition of catalase
by aminotriazole, and glutathione depletion by CDNB [25].
LLC-PK1 cells were prepared as described above. After aggrega-
tion, cells were exposed to 50 mM aminotriazole in combination
with 1 mM CDNB for six hours. Cytotoxicity was determined as
percent specific 51Cr release.
Measurement of cytotoxicity
51Cr release assay. Prior to the generation of a single cell
suspension, the LLC-PK1 cells were labeled overnight with
51Cr
(250 to 500 mMCi/mg Cr; Amersham Corp., Arlington Heights,
IL, USA). Following injury, the supernatant was aspirated from
each well, combined with two 100 ml PBS washings, and centri-
fuged at 1800 rpm (GPR Centrifuge; Beckman Instruments Inc.,
Palo Alto, CA, USA) for 10 minutes. The supernatant, represent-
ing cytosolic release of 51Cr, was separated from the cell pellet,
representing detached cells. The cell pellet and the remaining
attached cells on the plate were solubilized with sodium hydroxide
(1 M). The supernatant and solubilized cell fractions were counted
separately in a gamma counter (Gamma 7000; Beckman). The
mean spontaneous 51Cr release was determined by averaging the
supernatant 51Cr release for the PBS uninjured group and divid-
ing by total counts in the wells. The percent specific 51Cr release
was calculated as:
Percent specific 51Cr release
5
Cell supernate
2 Average spontaneous 51Cr release
Solubilized cells 1 ~Cell supernate
2 Average spontaneous 51Cr release!
LDH assay. Following injury, the entire 100 ml aliquot was
placed in a 1.5 ml microcentrifuge tube. The sample was centri-
fuged at 2000 rpm for 10 minutes and the supernatant was
carefully removed. The cell pellet was lysed with 0.1% Triton
X-100 (Research Organics, Inc., Cleveland, OH, USA) for 10
minutes at room temperature. LDH was quantitated by kinetic
absorption at 340 nm (Beckman DU 64 Spectrophotometer;
Beckman) after the addition of B-Nicotinamide adenine dinucle-
otide and Tris lactic acid buffer to 75 ml sample aliquot. Measure-
ments were obtained every 15 seconds and the slope was tabulated
from 0.5 to 2.5 minutes. Percent specific LDH release was
calculated as:
Percent specific LDH release
5
Cell supernate
2 Average spontaneous LDH release
Cell lysate 1 ~Cell supernate
2 Average spontaneous LDH release!
Statistical analysis
Statistical significance was defined as P , 0.05. The results were
recorded as mean 6 SEM. The significance of the differences was
analyzed by ANOVA, followed by the Student-Newman-Keuls
test for multiple group comparisons.
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RESULTS
Promotion of cell interactions by clusterin protected against
cell injury
No cell aggregation was seen when the cells were incubated
with PBS or BSA (50 mg/ml; Fig. 2). In contrast, incubation with
the known cell aggregation molecule fibrinogen (50 mg/ml),
resulted in an aggregation score of 3. Incubation with clusterin (50
mg/ml) resulted in an aggregation score of 4. Hydrogen peroxide
induced significant cytotoxicity in the PBS and BSA groups (P ,
0.05 vs. respective controls). Incubation with fibrinogen did not
protect against H2O2 induced injury despite an aggregation score
of 3. Clusterin incubation significantly decreased cytotoxicity
under control conditions (P , 0.05 vs. other controls) and
completely protected against H2O2 injury. Thus, at equal concen-
trations clusterin not only more effectively aggregated cells, but
also protected cells from exogenous oxidant injury.
Effect of increasing concentrations of clusterin on cytotoxicity
This study was performed to determine if protection from cell
injury was dependent on the concentration of clusterin and/or the
Fig. 1. Phase contrast photographs of a cell
suspension of LLC-PK1 cells illustrating the
grading system used for defining the promotion
of cell interactions by clusterin or fibrinogen. A
scale of 0 to 4 was used.
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degree of cell aggregation. As shown in Figure 3, clusterin
exhibited dose dependent aggregation. A dose of 2.5 mg/ml was
associated with an aggregation score of 1, 5 mg/ml with a score of
2, 10 mg/ml a score of 3 and 50 mg/ml a score of 4. H2O2 (1.5 mM)
resulted in significant injury to control cells. Clusterin induced cell
aggregation protected against cell injury at each concentration
(P , 0.05). Complete abrogation of cytotoxicity occurred at a
clusterin concentration of 2.5 mg/ml, which resulted in an aggre-
gation score of 1. Clusterin concentrations between 0 and 2.5
mg/ml showed no aggregation or protection (data not shown).
These results, using a different cytotoxicity assay (LDH release),
confirm the findings in Figure 2 that clusterin induced aggregation
is cytoprotective and demonstrate maximal protection may occur at
lower doses, associated with sub-maximal degrees of aggregation.
Fig. 2. Promotion of cell interaction by
clusterin protects against cell injury induced by
H2O2. The aggregation score was measured
after one hour using a scale of 0 to 4.
Cytotoxicity was measured by 51Cr release three
hours after addition of H2O2. Clusterin-induced
cell aggregation was protective under both
control and H2O2 injury conditions. (NS, not
significant; *P , 0.05). Number of
observations 5 6 each group. Symbols are: (M)
control; (o) H2O2 injury.
Fig. 3. Effect of increasing concentrations of
clusterin on cytotoxicity. The aggregation score
was measured after one hour using a scale of 0
to 4. Cytotoxicity was measured by LDH
release three hours after addition of H2O2.
Clusterin induced cell aggregation was
protective at all dosages tested. (NS, not
significant; *P , 0.05). Number of
observations 5 6 each group.
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Effect of increasing concentrations of clusterin, in the absence
of aggregation, on cytotoxicity
To determine if clusterin or the resultant promotion of cell
interactions was responsible for the cytoprotection seen, a dose
response study was performed in flat bottom plates, which com-
pletely inhibited clusterin-induced cell aggregation. As shown in
Figure 4, H2O2 (1.5 mM) resulted in significant injury to control
cells. Clusterin at doses of 20 and 50 mg/ml, but not lower doses,
protected against cell injury compared to the control group (P ,
0.05). The degree of protection was not as marked compared to
the experiments when cells were able to aggregate (Figs. 2 and 3).
These data suggest a partially protective effect of clusterin itself,
although a more profound protective effect was seen when
clusterin aggregated cells.
Effect of BSA, fibrinogen, and clusterin on oxidant stress
induced by CDNB and aminotriazole
To determine if promotion of cell interactions by clusterin was
protective in another model of oxidant injury, LLC-PK1 cells were
exposed to internally generated oxidant stress. Aminotriazole
together with CDNB compromised the cells ability to metabolize
oxidant species by inhibition of catalase and depleting glutathione
content. As shown in Figure 5, the vehicle control did not cause
injury. In contrast, the aminotriazole/CDNB combination injured
the cells, but not as severely as seen with exogenously adminis-
tered H2O2. No aggregation or protection was seen with the
addition of 50 mg/ml BSA. In this model both fibrinogen and
clusterin protected against injury despite differences in the degree
of cell aggregation.
DISCUSSION
The major finding of this study was the protective effects of
clusterin against oxidant injury in vitro. This protection was
specific for clusterin and in part dose-dependent. Cytoprotective
effects were found at a concentration of clusterin which only
minimally increased aggregation. In the complete absence of cell
aggregation clusterin had a less prominent but statistically signif-
icant protective effect. The beneficial effect was not an artifact of
the method used to quantitate cytotoxicity, as a beneficial effect of
clusterin was present when cytotoxicity was measured by both 51Cr
and LDH release. The effect was not due to restricted access of
H2O2 to critical cellular targets, since H2O2 is freely diffusible
across cellular membranes; nor was the protective effect due to
aggregation per se, since fibrinogen induced aggregation but
offered no protection, while lower doses of clusterin, which
evinced less cell aggregation as compared to higher doses, none-
theless, were as effective as the higher doses of clusterin in
affording protection.
When cells were injured in the aminotriazole/CDNB model of
internally generated oxidant stress both fibrinogen and clusterin
protected against injury. The reasons for these findings may reside
in the degree of cytotoxicity that was less in this model as
compared to injury induced by hydrogen peroxide. Additionally,
other damaging cellular effects of aminotriazole/CDNB may
occur independent of increased cellular generation of hydrogen
peroxide. Finally, protective responses elicited by these insults
may differ. CDNB depletes cellular glutathione content, the latter
representing a metabolite that facilitates degradation of H2O2
through the glutathione/glutathione peroxidase system. Amin-
otriazole effectively inhibits catalase, the latter representing the
other major antioxidant system that scavenges H2O2. The com-
bined treatment of cells with CDNB and aminotriazole cripples
the major pathways by which cellular degradation of H2O2 occurs
[25]. Increased cellular generation of H2O2 has been confirmed in
this model, while the administration of scavengers of H2O2 such
Fig. 4. Effect of increasing concentrations of
clusterin, in the absence of aggregation, on
cytotoxicity. The percent specific 51Cr release
was measured after injury in flat bottom plates,
which inhibited aggregation. Despite the
absence of aggregation, clusterin concentrations
of 20 and 50 mg/ml decreased cytotoxicity. (NS,
not significant; *P , 0.05). Number of
observations 5 6 each group.
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as pyruvate effectively protect in this model and decrease gener-
ation of H2O2 [25]. However, quantitative differences in the
concentration of H2O2 may exist between the models that could
influence both the degree of cytotoxicity and the mechanism of
cell death, since low doses of H2O2 cause apoptosis while higher
doses results in necrosis [28, 29]. In addition, there are effects of
CDNB and aminotriazole that may inflict cellular injury indepen-
dent of H2O2. Thus, differences exist between this model and the
model based upon the exogenous administration of H2O2. Not-
withstanding these differences, clusterin clearly protected in both
forms of oxidative stress whether instigated from reagent H2O2
exogenously applied or H2O2 endogenously generated as scaveng-
ing systems are compromised.
In prior studies, clusterin is strongly induced in models of acute
and chronic oxidative injury in the kidney [30]. In the light of such
induction by oxidant stress, we offer the speculation that expres-
sion of clusterin in diverse states of tissue injury may afford, at
least in part, a protective response to oxidative injury incurred in
such states. Indeed, it is increasingly recognized that antioxidant
defense mechanisms are recruited in response to oxidative injury,
and such mechanisms serve to limit the extent of injury that
ensues [31].
Clusterin-induced cell aggregation may protect against injury in
several different ways. Weinberg previously demonstrated de-
creased hypoxic injury when isolated proximal tubules were
studied as a high density pellet versus a low density suspension
[32]. This reduced susceptibility to injury was linked to a lower pH
in the pellet, an observation that has been confirmed in many
other settings [32, 33]. A similar mechanism is possible for the
protective effect of clusterin-induced cell aggregation. Aggrega-
tion of cells likely alters the cellular microenvironment in other
ways including changes in the availability of nutrients.
Other possible explanations include differences in the amount
of cell membrane accessible to oxidant injury, or better mainte-
nance of cell to cell contacts. The latter effect would facilitate
communication between cells, sharing of antioxidant defense
mechanisms, or stabilize intracellular structure through interac-
tion with the cell cytoskeleton. Maintenance of cell-substratum
contact may also prevent cell death by apoptosis [23].
A protective effect of clusterin has been demonstrated in
several different settings. Clusterin has been localized to the
immune deposits of a complement-mediated model of glomeru-
lonephritis, passive Heymann nephritis [34]. In the isolated rat
kidney model of this disease, depletion of clusterin leads to
increased proteinuria, greater deposition of terminal complement
components, and greater glomerular epithelial cell injury [2].
Overexpression of clusterin in a prostate cell line protects against
cell death induced by tumor necrosis factor [3]. Consistent with
this finding is the increased cell death observed in these cells when
clusterin production is inhibited by antisense transfection [3].
Clusterin expression is increased in the brains of patients with
Alzheimer’s disease where it has been localized to amyloid-b
deposits [35]. Clusterin interacts with amyloid-b 1-40 in a specific
manner. Clusterin can prevent the neurotoxicity of amyloid- b
1-40 in primary cultures of rat mixed hippocampus [4]. Oxidized
LDL, a pathogenic factor, but not normal LDL, induces clusterin
mRNA in cultured hepatic cells [5, 36]. Clusterin inhibits LDL-
induced lipid hydroperoxide formation and monocyte transmigra-
tion in co-cultures of human artery wall cells, suggesting a
protective role in atherosclerosis [5]. The mechanism proposed
for this effect is the removal of oxidation products by clusterin [5].
In addition, overexpression of clusterin protects L929 cells, a
fibroblast cell line, from tumor necrosis factor-a mediated cyto-
toxicity [6].
In conclusion, clusterin protects against models of oxidant
stress in vitro, whether generated by exogenously administered
hydrogen peroxide, or from endogenously produced peroxide, and
such protective effects can accrue from aggregative and nonag-
gregative properties of clusterin.
Fig. 5. Effect of bovine serum albumin (BSA),
fibrinogen, and clusterin on oxidant stress
induced by 1-chloro-1,4-dinitrobenzene (CDNB)
and aminotriazole. The aggregation score was
measured after one hour using a scale of 0 to 4.
Cytotoxicity was measured by 51Cr release three
hours after LLC-PK1 cells were injured with 50
mM aminotriazole (AT) and 1 mM 1-chloro-2,4-
dinitrobenzene (CDNB). Both fibrinogen and
clusterin protected against injury. (NS, not
significant; *P , 0.05). Number of
observations 5 6 each group.
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